Skip to main content
Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: N-Oleoyl dopamine induces IL-10 via central nervous system TRPV1 and improves endotoxemia and sepsis outcomes

Fig. 3

OLDA administration improves outcomes of antibiotic-treated or untreated S. aureus-induced pneumopathy. Wild-type mice were treated with S. aureus (MSSA, 1 × 107 CFU/25 g body weight, i.t.) and immediately thereafter with OLDA (10 mg/kg, i.v.) or vehicle (i.v.). They received a second dose of OLDA (10 mg/kg) or vehicle at 2 h. Additionally, mice were randomly assigned to receive vancomycin (10 mg/kg, i.p.) or carrier (i.p.) at 6 and 12 h. A1 Treatment with OLDA reduced MSS at 12 and 24 h in mice that did not receive vancomycin, and at 24 h in vancomycin-treated mice. A2 Treatment with OLDA reduced sepsis-induced hypothermia severity in vancomycin-treated and non-treated mice (10- to 12-week male, n = 12/group for mice that did not receive vancomycin, n = 5/group for mice that did not receive vancomycin). B, C Treatment with OLDA reduced B plasma levels of IL-6, CCL-2, CXCL-1, and C BAL fluid levels of IL-6, CCL2, CCL3, CXCL1 at T = 24 h after induction of S. aureus pneumonia (12-week male, n = 5/group). D Shows that OLDA treatment reduced lung capillary leak assessed by total protein in BAL fluid at 24 h in both mice treated with or without vancomycin (10- to 12-week male, n = 12/group for mice that did not receive vancomycin, n = 5/group for mice that did not receive vancomycin). E 24 h after inducing S. aureus pneumonia, CFU counts were not significantly in BAL fluid (n = 3–5/group), and blood (10- to 12-week male, n = 12/group for mice that did not receive vancomycin, n = 5/group for mice that did not receive vancomycin) of mice that did or did not receive OLDA, suggesting that OLDA does not impair blood bacterial clearance (10- to 12-week male, n = 42). *P < 0.05, **P < 0.01, ***P < 0.001, LPS-treated mice vehicle vs. OLDA, two-tailed Mann–Whitney U test at each time point

Back to article page